Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAT for Islet Transplant Engraftment
NCT02464878Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2017
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha1-proteinase inhibitor in type 1 diabetes mellitus (T1D), sponsored by Massachusetts General Hospital. Started Jan 2017; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02464878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464878.